Conditions: Healthy Volunteer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 18
Healthy volunteers: yes

Brief summary:
This Phase IV, single-blind , randomized, two-arm study will explore the pharmacodynamics effects of RoActemra/Actemra (tocilizumab) on neutrophil redistribution, function and survival in healthy subjects. Subjects will receive either a single dose of intravenous (IV) RoActemra/Actemra at a dose of 8 mg/kg over one hour on study Day 0 or placebo. Neutrophil kinetics data will be collected for all subjects up to Day 10 of the study. Following the last study visit on Day 10, all subjects will attend two further safety follow-up visits on Day 28 and Day 56.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: placebo intervention 2: tocilizumab [RoActemra/Actemra]
Intervention descriptions: intervention 1: Single i.v. infusion intervention 2: Single 8 mg/kg i.v. infusion

Protocol document: